Families-At-risk for Interstitial Lung Disease Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

125 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-15

Study Completion Date

2023-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The interstitial lung diseases (ILDs) are a family of closely related lung conditions characterized by alveolar inflammation, injury, and fibrosis not due to infection or neoplasia. While previously considered to be rare, a recent nationwide study found that idiopathic pulmonary fibrosis (IPF), a fibrotic ILD with a median survival of only 3.8 years, affects nearly 0.5% of older adults in the U.S. While pirfenidone and nintedanib slow the progression of IPF, neither reverses fibrosis nor prevents progression of the disease,and no studies to date have tested interventions that prevent the development of fibrotic ILDs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

NCT00470327

Interstitial Lung Diseases Idiopathic Pulmonary Fibrosis Sarcoidosis +1 more

RECRUITING

Individual Sensitivity for Interstitial Lung Diseases

NCT00741572

Interstitial Lung Diseases

COMPLETED

A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

NCT03261037

Idiopathic Pulmonary Fibrosis Interstitial Lung Disease

COMPLETED NA

Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives

NCT06036719

Interstitial Lung Diseases

RECRUITING

Mechanisms of Familial Pulmonary Fibrosis

NCT03437486

Familial Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Familial Interstitial Pneumonia

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The NHLBI has prioritized research focused on the primary prevention of chronic lung diseases, including ILD. The overall goal of this study is to conduct studies preparatory to and requisite for the testing of ILD preventative interventions.

In the current study, the investigators propose to examine the pulmonary histopathology and biology of early subclinical ILD in healthy adults with a first-degree relative with clinically diagnosed ILD. There are two currently accepted computed tomographic (CT)-based phenotypes of subclinical ILD: high attenuation areas (HAAs) and interstitial lung abnormalities (ILA). Investigators from Columbia University Medical Center have previously shown that HAA has strong construct validity as an imaging biomarker of early subclinical alveolar inflammation and fibrosis among community-dwelling adults using the Multi-Ethnic Study of Atherosclerosis (MESA), an ongoing NHLBI-funded prospective cohort study of 6,814 adults age 45 and older at enrollment in 2000-02. Investigators found that greater HAA at baseline was independently associated with reduced lung function and exercise capacity at 5-year follow-up, exertional dyspnea at 10-year follow-up, and elevated serum levels of matrix metalloproteinase-7 (MMP-7) and interleukin-6 (IL-6). ILA is a distinct qualitative and visually-identified early ILD phenotype on CT that has also shown strong construct validity for ILD. Neither HAA nor ILA has been validated histopathologically.

The lipoprotein substudy will examine the role of high density lipoproteins in patients with ILD. Patients with IPF have previously been shown to have low levels of high density lipoprotein (HDL) and high levels of low density lipoprotein (LDL). Investigators have previously shown that high levels of high-density cholesterol (HDL-C) are associated with a reduction in lung injury, inflammation and fibrosis (subclinical ILD) on CT in community-dwelling adults enrolled in the Multi-Ethnic Study of Atherosclerosis. These data are consistent with animal model data showing that treatment with apolipoprotein A-I (ApoA-I; the main component of HDL) attenuates lung fibrosis. Investigators at Columbia University Medical Center are therefore proposing to examine the associations of HDL and its main components (apolipoprotein A-I, apolipoprotein A-II, and paraoxonase-1) with clinical outcomes (FVC decline, death, lung transplantation and respiratory hospitalizations) and serum biomarkers of lung injury, inflammation and remodeling (SP-A, MMP-7, ICAM-1, IL-1, IL-18) in patients with ILD. Investigators will also explore the structure (using quantitative proteomics) and function (using a macrophage efflux assay and paraoxonase-1 activity assay) of HDL particles in adults with ILD and first-degree family members with subclinical ILD.

Obstructive sleep apnea (OSA) is highly prevalent among adults with interstitial lung disease (ILD) and maybe a risk factor based on our previous studies from MESA (https://www.mesa-nhlbi.org/) and other research studies completed at Columbia University Medical Center. Therefore, the investigators will examine the association between OSA and sub-clinical ILD in at-risk adults.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Interstitial Lung Disease Idiopathic Pulmonary Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FAR-ILD Proband Participants

There will be no interventions administered to this group, only data collection.

No interventions assigned to this group

FAR-ILD "At-Risk" Participants

There will be no interventions administered to this group, only data collection

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 35 years or older, however subjects who are 40 years old and above will undergo HRCT and subjects age 40-65 years old will be eligible to undergo bronchoscopy
* First-degree relative with one of the following clinical diagnoses:
* Idiopathic Pulmonary Fibrosis
* Idiopathic Non-Specific Interstitial Lung Disease (with fibrosis)
* Chronic Hypersensitivity Pneumonitis (with fibrosis)
* Unclassifiable Idiopathic Interstitial Pneumonia (with fibrosis)
* Patients with any ILD characterized by fibrosis on CT chest scan
* Ability to provide informed consent

* At least 50 years of age
* Smoked at least 1 pack a day for 30 years

* Has one of the following clinical diagnoses as per ATS guidelines:
* Idiopathic Pulmonary Fibrosis
* Idiopathic Non-Specific Interstitial Lung Disease (with fibrosis)
* Chronic Hypersensitivity Pneumonitis (with fibrosis)
* Unclassifiable Idiopathic Interstitial Pneumonia (with fibrosis)
* Patient with any ILD characterized by fibrosis on CT chest scan
* Ability to provide informed consent

Exclusion Criteria

* Known history of interstitial lung disease
* History of illicit drug use within the past year.
* Lower respiratory tract infection in the past 90 days.
* History of chest CT scan in the past year.
* Known history of heart failure or chronic kidney or liver disease.
* Pregnancy or Lactation

* No Living 1st degree relatives.

Minimum Eligible Age

35 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes